SCHEMBL29911570

SCHEMBL29911570

Cc1nc(-c2ccc3c(c2)CCN3C(=O)Cc2cc(F)cc(C(F)(F)F)c2)c2c(N)ncc(Cl)n12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 17/20 0.61
EIF2AK3 Q9NZJ5 4/20 0.57
NTRK1 P04629 1/20 0.46
CYP1A2 P05177 1/20 0.46
LCK P06239 1/20 0.46
YES1 P07947 1/20 0.46
RET P07949 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C8 P10632 1/20 0.46
CYP2D6 P10635 1/20 0.46
KIT P10721 1/20 0.46
CYP2C9 P11712 1/20 0.46
EIF2AK2 P19525 1/20 0.46
AXL P30530 1/20 0.46
CYP2C19 P33261 1/20 0.46
NEK4 P51957 1/20 0.46
MAP3K9 P80192 1/20 0.46
MAP3K10 Q02779 1/20 0.46
MERTK Q12866 1/20 0.46
PTK6 Q13882 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23059993 1.00 RIPK1 (0.61) RIPK1EIF2AK3NTRK1CYP1A2LCK
SCHEMBL2373928 0.76 RIPK1 (0.60) RIPK1EIF2AK3NTRK1CYP1A2LCK
SCHEMBL16156134 0.74 RIPK1 (0.60) RIPK1EIF2AK3NTRK1CYP1A2LCK
SCHEMBL30100854 0.73 EIF2AK3 (0.80) RIPK1EIF2AK3NTRK1CYP1A2LCK
SCHEMBL27191049 0.73 EIF2AK3 (0.80) RIPK1EIF2AK3NTRK1CYP1A2LCK
SCHEMBL869448 0.73 EIF2AK3 (1.00) RIPK1EIF2AK3NTRK1CYP1A2LCK
SCHEMBL13861464 0.72 EIF2AK3 (0.85) RIPK1EIF2AK3NTRK1CYP1A2LCK
SCHEMBL869164 0.72 EIF2AK3 (0.72) RIPK1EIF2AK3NTRK1CYP1A2LCK
SCHEMBL2389079 0.71 EIF2AK3 (0.67) RIPK1EIF2AK3NTRK1CYP1A2LCK
SCHEMBL2373766 0.68 EIF2AK3 (0.48) RIPK1EIF2AK3EIF2AK2EIF2AK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220348584-A1 PERK INHIBITING INDOLINYL COMPOUNDS HIBERCELL, INC. 2022-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348584-A1 PERK INHIBITING INDOLINYL COMPOUNDS ATF4, MAP3K10, EEF2K RIPK1 170/4885EIF2AK3 85/4885NTRK1 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.